Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddys yields...

    Dr Reddys yields positive results from phase 2b study of new psoriasis drug

    Farhat NasimWritten by Farhat Nasim Published On 2019-06-10T14:02:07+05:30  |  Updated On 16 Aug 2021 1:02 PM IST

    The detailed safety and efficacy data from the study would be presented in future dermatology conferences, reads Dr Reddy's (Dr Reddys) recent release.


    HYDERABAD: Dr Reddy's Laboratories Ltd Monday said it has obtained positive results in the phase-IIb study of its oral molecule PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.


    According to a press release from the city-based drug-maker, the detailed safety and efficacy data from the study would be presented in future dermatology conferences.


    Senior vice-president and head, proprietary products business of the company, Anil Namboodiripad said PPC-06 is an oral molecule with a novel mechanism of action that has the potential to address unmet medical needs of psoriasis patients.


    "The top-line data we are reporting today support our belief that PPC-06 may become the first approved oral prodrug of monomethyl fumarate (MMF) for treatment of moderate to severe plaque psoriasis in the US," the official said.


    Also Read: Dr Reddys Labs relaunches Zenatane-generic version of Accutane in US


    Further clinical development requirements would be discussed with the US FDA to support the approval of this product, he added.


    The most common adverse events (AEs) reported were lymphocytopenia, eosinophilia and gastrointestinal (GI) disorders, such as diarrhoea, nausea, abdominal pain and vomiting.


    "Given the positive clinical data in this study, PPC-06 may have the potential to serve as an important therapeutic option for psoriasis patients in a market with limited oral treatments. We thank all the patients, investigators and study staff whose ongoing participation helped us achieve this target, said Sagar Munjal, chief medical officer of Promius Pharma, the US subsidiary of Dr Reddy's.


    Also Read: Dr Reddys launches generic version of Cubicin to treat skin infections

    2b studyClinical TrialDermatologydermatology conferencesDr Reddy'sDr Reddy's LaboratoriesDr Reddy's Labsdr reddys trialDRLHyderabadoral treatmentphase 2bphase IIphase II studyPPC-06Psoriasis
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok